Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Probactive Biotech has signed an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilising composition of antitumor radioactive compounds and antitumor antibodies.
Subscribe to our email newsletter
Probactive Biotech said that it has combined medical-grade Iodine-131 and Yttrium-90 with antitumor antibodies, producing targeted anticancer activity.
The parts of the research and development program is expected to be completed at the Dalat Nuclear Research Institute in Vietnam.
However, the later human clinical trials will be conducted in Vietnam under the regulatory guidelines of the Ministry of Health, and also in compliance with FDA regulations.
Ngo, president and CEO of St Paul Biotech, said: “There is a thriving pharmaceutical industry in Vietnam, and the Dalat Nuclear Research Institute has been producing radionuclides for medical use for over 30 years. My company in the US has been engaged in developing antitumor antibodies, so this is a natural fit to co-develop these novel drugs.
“The competitive landscape for the pharmaceutical industry has changed. We can now utilise recognised international science and technological resources to develop advanced biopharmaceuticals for a fraction of the cost usually associated with drug development. The medical and economic benefit from this type of strategic alliance will be significant.”